Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry
Authors:
Open Access
- 2 April 2024
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-12
Abstract
Background: Indobufen is widely used in patients with aspirin intolerance in East Asia. The OPTION trial launched by our cardiac center examined the performance of indobufen based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). However, the vast majority of patients with acute coronary syndrome (ACS) and aspirin intolerance were excluded. We aimed to explore this question in a real-world population. Methods: Patients enrolled in the ASPIRATION registry were grouped according to the DAPT strategy that they received after PCI. The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. Propensity score matching (PSM) was adopted for confounder adjustment. Results: A total of 7135 patients were reviewed. After one-year follow-up, the indobufen group was associated with the same risk of MACCE versus the aspirin group after PSM (6.5% vs. 6.5%, hazard ratio [HR] = 0.99, 95% confidence interval [CI] = 0.65 to 1.52, P = 0.978). However, BARC type 2, 3, or 5 bleeding was significantly reduced (3.0% vs. 11.9%, HR = 0.24, 95% CI = 0.15 to 0.40, P < 0.001). These results were generally consistent across different subgroups including aspirin intolerance, except that indobufen appeared to increase the risk of MACCE in patients with ACS. Conclusions: Indobufen shared the same risk of MACCE but a lower risk of bleeding after PCI versus aspirin from a real-world perspective. Due to the observational nature of the current analysis, future studies are still warranted to further evaluate the efficacy of indobufen based DAPT, especially in patients with ACS. Trial registration: Chinese Clinical Trial Register (https://www.chictr.org.cn); Number: ChiCTR2300067274.Keywords
Funding Information
- National Program on Key Basic Research Project of China (2019YFC0840601, 2022YFC2407002)
- National Natural Science Foundation of China (T2288101, 82170338, 81970295, 81870267)
- Shanghai Clinical Research Center for Interventional Medicine (19MC1910300)
- Grant of Shanghai Shenkang on Key Clinical Research Project (SHDC2020CR2015A, SHDC12019104)
- Grant of Shanghai Science and Technology Committee (20JC1410800)
- Key Medical and Health Projects of Xiamen Province (3502Z20204004)
- Zhongshan Hospital (2021ZSGG07, zhupei2021-012)
This publication has 25 references indexed in Scilit:
- Endoscopic Evaluation of the Effects of Indobufen and Aspirin in Healthy VolunteersAmerican Journal of Therapeutics, 2004
- Aspirin Use Post-Acute Coronary Syndromes: Intolerance, Bleeding and DiscontinuationJournal of Thrombosis and Thrombolysis, 2003
- Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyThe Lancet, 2001
- Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgeryCoronary Artery Disease, 1998
- Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial FibrillationStroke, 1997
- A Prostacyclin-sparing Effect of Indobufen vs. AspirinThrombosis and Haemostasis, 1996
- Effects of short-term treatment with the thromboxane synthesis blocker indobufen on pressor and depressor humoral factors in healthy humans.1995
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- IndobufenDrugs, 1992
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJACC, 1988